The PD-1 inhibitor sasanlimab showed anti-tumor activity and manageable safety in combination with BCG induction and maintenance compared with standard of care in patients with BCG-naïve high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback